Jay Moorin
Directeur/Membre du Conseil chez Equinox Funds Trust
Postes actifs de Jay Moorin
Sociétés | Poste | Début | Fin |
---|---|---|---|
Equinox Funds Trust | Directeur/Membre du Conseil | - | - |
Historique de carrière de Jay Moorin
Anciens postes connus de Jay Moorin
Sociétés | Poste | Début | Fin |
---|---|---|---|
ProQuest Management LLC
ProQuest Management LLC Investment ManagersFinance ProQuest Management LLC (ProQuest Management) is a venture capital firm founded in 1998 by Jay Moorin. The firm headquartered in Naples, Florida. | Fondateur | 18/09/2009 | 31/12/2023 |
Private Equity Investor | 01/01/1998 | 31/12/2023 | |
EAGLE PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 01/03/2007 | 30/12/2013 |
Président | 30/12/2013 | 28/06/2016 | |
Independent Dir/Board Member | 01/03/2007 | 28/06/2016 | |
PEGASI ENERGY RESOURCES CORPORATION | Directeur/Membre du Conseil | 31/01/2014 | 22/06/2015 |
Independent Dir/Board Member | 31/01/2014 | 22/06/2015 | |
MIRATI THERAPEUTICS | Directeur/Membre du Conseil | 01/01/2007 | 14/06/2011 |
Gloucester Pharmaceuticals, Inc.
Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA | Directeur/Membre du Conseil | - | 26/04/2011 |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Directeur/Membre du Conseil | 01/06/2001 | 19/09/2007 |
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Directeur/Membre du Conseil | 01/12/2001 | 08/01/2006 |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Directeur Général | 01/01/1987 | 31/12/1997 |
Président | 01/01/1987 | 31/12/1997 | |
░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ | - |
░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░ ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - | |
░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░░ ░░░░░░░ ░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - | - |
Formation de Jay Moorin
University of Michigan | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 21 |
Canada | 2 |
Opérationnelle
Director/Board Member | 14 |
Chairman | 3 |
Corporate Officer/Principal | 3 |
Sectorielle
Health Technology | 14 |
Health Services | 4 |
Finance | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 4 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
MERSANA THERAPEUTICS, INC. | Health Technology |
EAGLE PHARMACEUTICALS, INC. | Health Technology |
ARNO THERAPEUTICS, INC. | Health Technology |
Entreprise privées | 16 |
---|---|
Bear, Stearns & Co., Inc.
Bear, Stearns & Co., Inc. Investment Banks/BrokersFinance Bear, Stearns & Co., Inc. is a global investment banking, securities trading and brokerage firm located in New York City with additional offices in Dallas, Boston and San Francisco. The firm is a subsidiary Bear Sterns Cos., Inc. (NYSE: BSC). Their equity research team consists of senior analysts located throughout the world. In addition to domestic coverage, they have research teams focusing on Latin America, Asia and Europe. The analysts use a bottom-up approach to stock selection. The Bear Stearns fixed-income research department provides coverage of every sector of the fixed-income universe. The financial analytics and structured transactions group (F.A.S.T) provides investment research, fixed-income portfolio management and analytical systems, trading technology and general financial expertise. The group also provides a broad range of services to financial institutions including asset-liability management, balance sheet restructuring, receivables-based financing analysis, security and portfolio analysis, peer analysis, and historical and real-time market-based information. | Finance |
Genaera Corp.
Genaera Corp. Pharmaceuticals: MajorHealth Technology Genaera Corp. develops drugs for asthma, cancer, cystic fibrosis and age-related macular degeneration. It is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. It's products include EVIZON, to treat ophthalmic indications, specifically age-related macular degeneration. Squalamine lactate, for the treatment of cancerous solid tumors. It's third product candidate, LOMUCIN to treat the overproduction of mucus secretions involved in chronic respiratory disease. Fourth product candidate, interleukin-9 antibody, is a respiratory treatment based on the discovery of a genetic cause of asthma. It also has a number of discovery research programs focused on the treatment of obesity, infectious diseases and inflammatory disorders. The company is headquartered in Plymouth Meeting, PA. | Health Technology |
Pharmion Corp.
Pharmion Corp. Pharmaceuticals: MajorHealth Technology Pharmion Corp. engages in the development and commercialization of products for the treatment of hematology and oncology patients. It has operations in Switzerland, Israel, and Philippines. The company was founded by Patrick J. Mahaffy in 1999 and is headquartered in Boulder, CO. | Health Technology |
ProQuest Management LLC
ProQuest Management LLC Investment ManagersFinance ProQuest Management LLC (ProQuest Management) is a venture capital firm founded in 1998 by Jay Moorin. The firm headquartered in Naples, Florida. | Finance |
Gloucester Pharmaceuticals, Inc.
Gloucester Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Gloucester Pharmaceuticals, Inc. develops products for the treatment of cancer patients. Its programs include cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), and multiple myeloma. The company was founded in May 2003 and is headquartered in Cambridge, MA | Health Technology |
Mevion Medical Systems, Inc.
Mevion Medical Systems, Inc. Medical SpecialtiesHealth Technology Mevion Medical Systems, Inc. provides proton therapy systems for cancer centers, clinicians and patients worldwide. Its MEVION S250 Series is designed to deliver proton therapy treatments, optimizing both the outcomes and the economics of proton therapy. Its products include Mevion S250i with hyperscan and Mevion 250mx. The company was founded by Kenneth A. Gall in 2004 and is headquartered in Littleton, MA. | Health Technology |
Pegasi Energy Resources Corp.
Pegasi Energy Resources Corp. Oil & Gas ProductionEnergy Minerals Pegasi Energy Resources Corp. is an organic growth-oriented independent energy company, which engages in the exploration, development, and production of oil and natural gas. It currently holds interest in properties located in Cass and Marion Counties, Texas, home to the Rodessa oil field. The company was founded in March 2007 and is headquartered in Dallas, TX. | Energy Minerals |
Equinox Funds Trust | Miscellaneous |
ACMI Corp.
ACMI Corp. Medical SpecialtiesHealth Technology ACMI Corp. used to design, manufacture and market medical devices. Its products were diagnostic & therapeutic endoscopic instrumentation products. The company was founded in 1908 by Reinhold Wappler and was headquartered in Southborough, MA. | Health Technology |
Epic Therapeutics, Inc.
Epic Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Baxter International, Inc., Epic Therapeutics, Inc. is a company that develops therapeutic products used as injections or inhalation. The company is based in Norwood, MA. Epic Therapeutics was acquired by Baxter Healthcare Corp. on November 11, 2002. | Health Technology |
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. BiotechnologyHealth Technology Mirati Therapeutics, Inc. operates as a clinical-stage oncology company. engages in the development of novel therapeutics. The firm's products target the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995, and is headquartered in San Diego, CA. | Health Technology |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
Guava Technologies, Inc.
Guava Technologies, Inc. BiotechnologyHealth Technology Guava Technologies, Inc. develops, manufactures and commercializes cytometry systems for cellular analyses. Its products include Guava Personal Cell Analysis systems, Guava PCA, Guava PCA-96, and Guava EasyCyte systems. The company was founded by Goix J. Philippe in 1998 and is headquartered in Hayward, CA. | Health Technology |
Acurian, Inc.
Acurian, Inc. Medical/Nursing ServicesHealth Services Acurian, Inc. provides clinical trial patient recruitment and retention solutions for the life sciences industry. It offers recruitment feasibility, site identification and selection, patient recruitment and retention services. The firm also provides the recruitment manager platform or database that features feasibility and project management capabilities. The company was founded by Lance D. Converse, David Restrepo and Leslie D. Michelson in 1998 and is headquartered in Horsham, PA. | Health Services |
Aires Pharmaceuticals, Inc.
Aires Pharmaceuticals, Inc. Medical/Nursing ServicesHealth Services Aires Pharmaceuticals, Inc. develops drugs to treat pulmonary disorders. It offers Aironite, an inhaled drug that is used to treat adult and pediatric pulmonary hypertension, cystic fibrosis, pneumonia and other respiratory infections. The company was founded by Wendy S. Johnson in 2006 and is headquartered in San Diego, CA. | Health Services |
Predictive Biosciences, Inc.
Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | Health Services |
- Bourse
- Insiders
- Jay Moorin
- Expérience